[1]刘丁铭,程亚玲,杨红祥,等.利伐沙班与华法林在心房颤动患者经皮冠状动脉介入治疗术后临床应用效果对比研究[J].陕西医学杂志,2024,(3):395-398,406.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.023]
　LIU Dingming,CHENG Yaling,YANG Hongxiang,et al.Comparative study of clinical efficacy of rivaroxaban and warfarin in patients with atrial fibrillation after percutaneous coronary intervention[J].,2024,(3):395-398,406.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.023]
点击复制

利伐沙班与华法林在心房颤动患者经皮冠状动脉介入治疗术后临床应用效果对比研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
395-398,406
栏目:
药物与临床
出版日期:
2024-03-05

文章信息/Info

Title:
Comparative study of clinical efficacy of rivaroxaban and warfarin in patients with atrial fibrillation after percutaneous coronary intervention
作者:
刘丁铭; 程亚玲; 杨红祥; 甘 萍; 文俊杰
(四川大学华西广安医院心内科,四川 广安 638000)
Author(s):
LIU Dingming; CHENG Yaling; YANG Hongxiang; GAN Ping; WEN Junjie
(Department of Cardiology,Guang'an People's Hospital,Guang'an 638000,China)
关键词:
心房颤动;  利伐沙班;  华法林;  经皮冠状动脉介入治疗;  安全性
Keywords:
Atrial fibrillation;  Rivaroxaban;  Warfarin;  Percutaneous coronary intervention;  Safety
分类号:
R 541.75
DOI:
DOI:10.3969/j.issn.1000-7377.2024.03.023
文献标志码:
A
摘要:
目的:比较利伐沙班与华法林在心房颤动患者经皮冠状动脉介入治疗(PCI)术后的临床应用效果。方法:选取接受PCI的心房颤动患者128例为研究对象,随机分为两组,各64例。对照组在PCI术后给予华法林+替格瑞洛+阿司匹林治疗,观察组给予利伐沙班+替格瑞洛+阿司匹林治疗。比较两组凝血功能指标、心肌损伤指标、心功能指标、心肌梗死溶栓治疗(TIMI)血流分级分布和主要不良心血管事件(MACE)发生情况。结果:治疗1年后,观察组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、凝血酶时间(TT)水平及左心室射血分数(LVEF)高于对照组,左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)低于对照组(均P<0.05)。治疗2周后,观察组肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、超敏C-反应蛋白(hs-CRP)低于对照组(均P<0.05)。治疗1年后,在TIMI血流分级分布方面,观察组优于对照组(P<0.05)。两组MACE总发生率相当(P>0.05)。结论:在心房颤动患者PCI术后应用利伐沙班效果优于华法林,可改善凝血功能和TIMI血流分级,减少心肌损伤,且安全性与华法林相当。
Abstract:
Objective:To compare the clinical efficacy of rivaroxaban and warfarin in patients with atrial fibrillation after PCI.Methods:A total of 128 patients with atrial fibrillation who underwent PCI were selected as the study objects and randomly divided into two groups,64 cases in each.The control group was given warfarin,ticagrelor and aspirin after PCI,and the observation group was given rivaroxaban,ticagrelor and aspirin.The coagulation function indexes,myocardial injury indexes and cardiac function indexes,TIMI blood flow classification distribution and occurrence of major adverse cardiovascular event(MACE).Results:After 1 year of treatment,PT,APTT,FIB,TT levels and LVEF in observation group were higher than those in control group,LVESD and LVEDD were lower than those in control group(all P<0.05).After 2 weeks of treatment,cTnI,CK-MB and hs-CRP in observation group were lower than those in control group(all P<0.05).After 1 year of treatment,the observation group was better than the control group in TIMI blood flow classification distribution(P<0.05).The total incidence of MACE was similar between two groups(P>0.05).Conclusion: Rivaroxaban is better than warfarin in patients with atrial fibrillation after PCI,can improve coagulation function and TIMI blood classification,reduce myocardial injury,and is as safe as warfarin.

参考文献/References:

[1] 何芸,张卫卫,孔祥云.血清白细胞介素-6、肿瘤坏死因子-α、活性氧在食管癌术后并发心房颤动患者体内表达水平及检测意义[J].陕西医学杂志,2022,51(7):816-819.
[2] 潘熠,赵玲茏,郑相颖,等.活血化瘀汤治疗急性心肌梗死伴心房颤动临床研究[J].陕西中医,2020,41(11):1595-1597,1601.
[3] BOCCHINO P P,ANGELINI F,TOSO E.Atrial fibrillation and coronary artery disease:A review on the optimal use of oral anticoagulants[J].Rev Cardiovasc Med,2021,22(3):635-648.
[4] 张晗,邵兴慧,王娟,等.心房颤动合并急性冠脉综合征或经皮冠状动脉介入治疗术后双联或三联抗栓治疗的对照研究[J].中华心律失常学杂志,2022,26(2):165-170.
[5] 许贤彬,卢旭升,陈尔周,等.不同INR对冠心病合并房颤患者血栓栓塞事件以及主要不良心血管事件的影响[J].河北医学,2020,26(4):644-649.
[6] POTPARA T S,MUJOVIC N,PROIETTI M,et al.Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions:Meta-analysis of pooled data from the PIONEER AF-PCI,RE-DUAL PCI,and AUGUSTUS trials[J].Europace,2020,22(1):33-46.
[7] RANDHAWA M S,VISHWANATH R,RAI M P,et al.Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease:A systematic review and meta-analysis[J].JAMA Netw Open,2020,3(4):e202175.
[8] 顾敏,顾翔.老年非瓣膜性房颤患者华法林抗凝强度的研究进展[J].中华老年多器官疾病杂志,2019,18(3):232-236.
[9] HINDRICKS G,POTPARA T,DAGRES N,et al.2020 ESC guidelines for the diagnosis and management of atrial fibrilloraation developed in collabtion with the European Association for Cardio-Thoracic Surgery(EACTS):The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC[J].Eur Heart J,2021,42(5):373-498.
[10] KUNADIAN V,GIBSON C M.Thrombolytics and myocardial infarction[J].Cardiovasc Ther,2012,30(2):e81-e88.
[11] 韩乔木,宫丽鸿,吴启华,等.化痰祛瘀方对心房颤动大鼠血管细胞黏附分子-1及血管性血友病因子的影响[J].陕西中医,2022,43(9):1180-1184.
[12] LOPES R D,HONG H,HARSKAMP R E,et al.Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention:An updated network meta-analysis[J].JAMA Cardiol,2020,5(5):582-589.
[13] 黄柏松,丛洪良.高危血栓栓塞风险心房颤动患者支架置入术后不同三联抗栓方案效果的临床观察[J].中国心血管杂志,2022,27(2):139-144.
[14] 李丽娟,马宇凌.利伐沙班片联合氯吡格雷片和/或阿司匹林肠溶片用于心房颤动患者经皮冠状动脉介入治疗术后的临床研究[J].中国临床药理学杂志,2019,35(19):2207-2210.
[15] 冀忠英,李学文,张雪娥.CHA2DS2-VASc评分联合HAS-BLED评分应用于非瓣膜性房颤抗凝治疗的观察[J].中国药物与临床,2019,19(5):814-815.
[16] KIRCHHOF P,EZEKOWITZ M D,PURMAH Y,et al.Effects of rivaroxaban on biomarkers of coagulation and inflammation:A post hoc analysis of the X-VeRT trial[J].TH Open,2020,4(1):e20-e32.
[17] 邢宇,栗印军.利伐沙班、达比加群酯和华法林用于高龄非瓣膜性房颤病人抗凝治疗的有效性和安全性对比研究[J].中西医结合心脑血管病杂志,2019,17(3):411-413.
[18] STEFFEL J,COLLINS R,ANTZ M,et al.2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J].Europace,2021,23(10):1612-1676.
[19] 李世樱,杨玲英,张栋梅,等.miR-499-5p靶向调控钙通道电压依赖性β1蛋白在慢性心房颤动、心房重构中的作用研究[J].陕西医学杂志,2021,50(4):403-408.
[20] ZHANG Q,ZHANG Z,CHEN W,et al.Rivaroxaban,a direct inhibitor of coagulation factor Ⅹa,attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways[J].PeerJ,2023,11(1):e16097.
[21] RUBBOLI A,VALGIMIGLI M,CAPODANNO D,et al.Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention:Questions(and answers)in chronological sequence[J].Eur Heart J Cardiovasc Pharmacother,2021,7(1):68-73.
[22] 柳茜,罗欣月,朱春玲,等.慢性肾脏病合并房颤的机制及口服抗凝用药的研究进展[J].海南医学,2021,32(23):3115-3118.
[23] 陈永刚,王红卫,许莹.利伐沙班对稳定性冠心病合并房颤患者临床疗效及脑血管意外事件发生率的影响研究[J].贵州医药,2021,45(5):759-761.
[24] 董权平,黄远波,王善花,等.利伐沙班或华法林治疗非瓣膜性心房颤动发生消化道出血的影响因素分析[J].中国新药与临床杂志,2022,41(7):426-430.
[25] 李宇,冯晓俊,樊晖晖,等.新型口服抗凝药和华法林对<75岁和≥75岁房颤患者的有效性和安全性的meta分析[J].中国现代应用药学,2021,38(18):2262-2272.
[26] ZHOU S,XIAO Y,ZHOU C,et al.Effect of rivaroxaban vs enoxaparin on major cardiac adverse events and bleeding risk in the acute phase of acute coronary syndrome:The H-REPLACE randomized equivalence and noninferiority trial[J].JAMA Netw Open,2023,6(2):e2255709.
[27] 赵紫楠,朱愿超,梁良,等.急性冠状动脉综合征患者应用新型口服抗凝药后发生大出血及心血管事件风险的meta分析[J].药物不良反应杂志,2019,21(4):244-251.

相似文献/References:

[1]杨延洁,周慧龙△.不同双抗血小板疗程对冠心病合并房颤PCI术后患者远期预后的影响*[J].陕西医学杂志,2019,(12):1653.
[2]彭茂轩,高彦斌,方海林△.间歇性充气加压装置联合利伐沙班应用于脊柱手术后血栓形成预防效果观察[J].陕西医学杂志,2020,49(5):568.
　PENG Maoxuan,GAO Yanbin,FANG Hailin..Preventive effect of intermittent pneumatic compression device combined with rivaroxaban on thrombosis after spinal surgery[J].,2020,49(3):568.
[3]张 晨,宋国瑞,刘子歌,等.低分子肝素与利伐沙班预防全膝关节置换术后静脉血栓成形的疗效及安全性对比分析*[J].陕西医学杂志,2020,49(9):1153.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.025]
　ZHANG Chen,SONG Guorui,LIU Zige,et al.Comparative analysis of the efficacy and safety of low molecular weight heparin and rivaroxaban in prevention of venous thrombosis after TKA[J].,2020,49(3):1153.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.025]
[4]王桃桃,翟奇辉,鲁张波,等.肺癌患者急性非大面积肺栓塞的影响因素及低分子量肝素联合利伐沙班治疗的临床疗效[J].陕西医学杂志,2025,54(4):519.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.017]
　WANG Taotao,ZHAI Qihui,LU Zhangbo,et al.Factors affecting acute non-massive pulmonary embolism in patients with lung cancer and clinical efficacy of low molecular weight heparin combined with rivaroxaban therapy[J].,2025,54(3):519.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.017]

备注/Memo

备注/Memo:
基金项目:四川省转移支付项目(2021ZYZFSY01); 四川省广安市人民医院高质量发展基金资助项目(21FZ009)
更新日期/Last Update: 2024-03-05